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Abstract
Annexin A1 (Anxa1) is expressed specifically on the surface of the tumor 
vasculature. Previously, we demonstrated that a carbohydrate-mimetic peptide, 
designated IF7, bound to the Anxa1 N-terminal domain. Moreover, intravenously 
injected IF7 targeted the tumor vasculature in mouse and crossed tumor endothelia 
cells to stroma via transcytosis. Thus, we hypothesized that IF7 could overcome 
the blood–brain barrier to reach brain tumors. Our studies in brain tumor model 
mice showed that IF7 conjugated with the anti-cancer drug SN38 suppressed brain 
tumor growth with high efficiency. Furthermore IF7-SN38-treated mice mounted 
an immune response to brain tumors established by injected tumor cells and shrank 
those tumors in part by recruiting cytotoxic T-cells to the injection site. These 
results suggest that Anxa1-binding peptide IF7 represents a drug delivery vehicle 
useful to treat malignant brain tumors. This chapter describes the unique develop-
ment of IF7-SN38 as a potential breakthrough cancer chemotherapeutic.
Keywords: carbohydrate mimetic peptides, phage display, annexin 1(Anxa1),  
blood–brain barrier (BBB), glioblastoma, chemotherapy, SN-38, CPT-11, 
geldanamycin (GA), cytotoxic T cell, CD8
1. Introduction
Brain malignancies are difficult to treat due to the blood–brain barrier (BBB), a 
layer of endothelial cells that separates the circulation from the brain and protects 
the central nervous system from pathogens and toxic materials [1, 2]. Although 
brain tumor cells cultured in vitro respond to several anti-cancer drugs, brain 
tumors in vivo do not due to the BBB. Chemotherapeutic drugs capable of passing 
the BBB are small lipopholic molecules of less than 500 Da [3], as exemplified by 
temozolomide [4–6]. Numerous investigators have attempted to overcome this 
hurdle using brain vasculature surface receptor-mediated proteins [7, 8], tumor-
penetrating peptides [4, 9, 10], or nanoparticles [11, 12]. However, these attempts 
have not yet achieved clinically satisfactory results. On the other hand, tumor 
vasculature surrounding a brain tumor is chaotic, allowing large molecules and 
nanoparticles to overcome the BBB by passing through gaps between endothe-
lial cells [13]. However, as this approach relies on passive diffusion, drugs must 
be administered at the maximum tolerable dose, causing adverse side effects. 
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Thus, efficient treatment of brain tumors requires both tumor vasculature targeting 
and penetration by a therapeutic to overcome the BBB. In this chapter, we describe 
the carbohydrate mimetic 7-mer peptide IF7, which serves as a highly specific tumor 
vasculature-targeting vehicle. When conjugated to the anti-cancer drug SN-38 
and injected into mouse brain tumor models, IF7-SN38 has a potent anti-tumor 
effect. IF7-SN38 represents a potential breakthrough chemotherapeutic in brain 
malignancies.
2. IF7 peptide: how was it identified?
IF7 is a linear 7-mer peptide with the sequence IFLLWQR [14]. This peptide 
is considered a carbohydrate mimetic, as it was identified in studies of cancer 
cell surface carbohydrates [15, 16]. Epithelial cancer cells express complex car-
bohydrate antigens, and some serve as ligands for carbohydrate binding proteins 
known as selectins. We hypothesized that interaction between selectin and selectin 
ligand functions in carbohydrate-dependent tumor cells colonization to the lung 
[17], in a manner similar to that seen in selectin-dependent hematogenous liver 
 metastasis [18, 19].
Our goal, however, was challenging, as chemical synthesis of oligosaccharides 
as elaborate as the selectin ligand involved tedious, time-consuming and therefore 
expensive steps. To overcome this problem, we used phage display technology to 
identify carbohydrate mimetic peptides that might function as an E-selectin ligand. 
However, initially when we used E-selectin as the target, we did not obtain a phage 
clone. We then took a different approach and screened peptides for ability to bind 
Figure 1. 
E-selectin binding of linear 7-mer peptide sequences. Phage clones were selected by mouse monoclonal anti-
Lewis A antibody (clone 7LE). Each cloned phage was added to microtiter plate wells coated with E-selectin-
IgG chimeric protein. Phage binding to E-selectin was tested in the presence or absence of 1 mM CaCl2. The best 
binder, IELLQAR, was designated I-peptide.
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anti-carbohydrate antibodies that recognize E-selectin ligands or related carbo-
hydrates. Using this approach, we succeeded in identifying a linear 7-mer peptide 
from a phage display library. Since carbohydrate antigen specificity is determined 
by 3–4 carbohydrate residues of 600–800 Da, we assumed that a 7-mer peptide of 
770 Da would mimic a carbohydrate antigen. The phage library screening yielded a 
series of peptides with the consensus sequence IXLLXXR [15] (Figure 1).
Among those peptides, the strongest binder to E-selectin was IELLQAR, which 
we designated I-peptide. Chemically synthesized I-peptide inhibited hematogenous 
colonization of the tumor cells to the lung in mouse [15]. However, in E/P-selectin 
doubly-deficient mice, tumor cells expressing selectin ligand carbohydrate colo-
nized the lung, and that colonization was inhibited by I-peptide [20]. These results 
indicated that I-peptide receptor is not an E- or P-selectin and raised the question of 
what receptor I-peptide bound to in lung vasculature?
To identify the I-peptide receptor, we injected mice intravenously with a bioti-
nylation reagent plus I-peptide-displaying phage or controls. We then isolated lung 
tissue and immunoprecipitated lysates with rabbit anti-phage antibody or control 
IgG. When we resolved immunoprecipitates on SDS-PAGE, we detected two in 
vivo biotinylated proteins as 40 kDa and 20 kDa bands on a peroxidase avidin blot 
(Figure 2). We isolated respective candidate receptor proteins from lung membrane 
fractions using I-peptide affinity chromatography and proteomic analysis and 
Figure 2. 
Detection of I-peptide receptor(s) on the surface of lung endothelial cells by in vivo biotinylation. Mice were 
injected intravenously with either PBS (lane 1) or a biotinylation reagent (lanes 2–6), followed by intravenous 
injection of I-peptide-displaying (lanes 3 and 4) or control (lanes 5 and 6) phage. After perfusion of mice with 
PBS, lungs were isolated and phage was immunoprecipitated with rabbit anti-phage antibody (lanes 4 and 
6) or rabbit IgG (lane 3 and 5). Immunoprecipitates were resolved on SDS-PAGE and biotinylated proteins 
detected using a peroxidase avidin blot.
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found them to be the pre-mRNA splicing factor (Sfrs) and annexin A1 (Anxa1) 
[21]. Recombinant Sfrs proteins showed binding to I-peptide and a series of carbo-
hydrates, whose structures overlapped with selectin ligand [21].
Full-length Anxa1 is 37 kDa; therefore, we considered the 20 kDa band seen 
in Figure 2 to be a fragment of the full-length protein. By the time we identi-
fied Anxa1 fragments, Oh et al. had undertaken rigorous subtractive proteomics 
analysis and identified Anxa1 as a specific vasculature surface marker of malignant 
tumors [22]. Thus, we hypothesized that I-peptide or related peptides could serve 
as tumor vasculature-specific drug delivery vehicles via binding to Anxa1. We then 
rescreened a series of phage clones for tumor-targeting activity and identified an 
Anxa1-binding, but not Sfrs-binding, phage clone displaying IFLLWQR peptide 
(Figure 3). Moreover, tumor targeting was inhibited in the presence of an anti-
Anxa1 antibody specific to the N-terminal region (Figure 4) [21].
Figure 3. 
In vivo phage targeting specificity to tumor and normal lung. Subcutaneous B16 tumor-bearing mice were 
intravenously injected with each phage clone, and phage number in the tumor and lung was determined by a 
colony-forming assay. Note that IFLLWQR- or IF7 peptide-displaying phage exclusively targeted the tumor but 
not lung tissue.
Figure 4. 
In vivo tumor and organ targeting by IF7-peptide-displaying phage. IF7-displaying phage were injected 
intravenously into subcutaneous B16 tumor-bearing mice. Note that IF7-displaying phage targeted the tumor 
but not normal organs. Tumor targeting by IF7 phage was inhibited by pre-injection of mice with rabbit 
polyclonal anti-Anxa1 (N-19) antibody directed to the Anxa1 N-terminal domain but not by injection with 
control rabbit IgG.
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3. Targeting the tumor vasculature by IF7 peptide
Next, to visualize tumor targeting by chemically synthesized IF7 peptide, we 
used intravital microscopy, in which tumor was implanted in a dorsal skinfold 
chamber [23] visualized tumor vasculature targeting of IF7 under fluorescence 
microscopy. Green fluorescent Alexa 488-labeled IF7 was injected intravenously 
and green fluorescent signals were recorded over time by video [14]. Fluorescence 
appeared in the tumor within 30 sec of injection and increased over time 
(Figure 5). Analysis of tumor tissue sections taken 15 minutes after A488-IF7 
injection indicated fluorescent signals as a punctate staining pattern over endo-
thelial cells (Figure 6, upper). By 40 min, green fluorescence had moved to the 
stroma (Figure 6, lower), suggesting that IF7 passed through endothelial cells and 
penetrated the tumor stroma where cancer cells reside. The punctate appearance of 
Alexa 488 staining suggests that IF7-bound to Anxa1 is internalized by endothelial 
cells, possibly in vesicles. Anxa1 on the tumor vasculature surface reportedly local-
izes in caveolae and, when bound by anti-Anxa1 antibody, the complex is internal-
ized into vesicles transported to the basal surface via transcytosis [24]. Accordingly, 
we concluded that IF7 bound to Anxa1 on the tumor vasculature was transported 
from the luminal surface to the basal membrane via transcytosis through endo-
thelial cells and likely released to the tumor stroma. Therefore, we asked whether 
IF7-conjugated chemotherapeutics could cross the BBB to deliver a cytotoxic drug 
to brain stroma.
To test this possibility we injected A488-IF7 through the tail vein into brain 
tumor-bearing mice and then prepared sections of mouse brain tissue 20 minutes 
later. Fluorescence microscopy analysis revealed bright fluorescence in tumor 
tissue [25]. At higher magnification A488-IF7 fluorescent signals were evident 
in cytoplasm and/or nuclei of cancer cells. Micrographs of representative organs 
from the same mouse showed no significant fluorescent signals in normal organs. 
Brain tumors and representative organs from an animal injected with A488-C(RR) 
peptide control showed background fluorescence. These results strongly suggest 
that intravenously-injected IF7 crosses the BBB to target and penetrate brain tumor 
vasculature and reach cancer cells [25].
Figure 5. 
Intravital microscopy of Alexa 488-conjugated IF7 peptide. Mouse lung carcinoma LL/2 tumors were 
inoculated in the skin of nude mice of a dorsal skin-fold chamber [23]. A488-IF7 was injected intravenously 
and green fluorescent signals were video-recorded and detected at the indicated times.
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4.  The ANXA1 N-terminal domain is present on the tumor vasculature 
surface
Several lines of evidence suggest that IF7 binds to human and mouse Anxa1 at 
the N-terminal domain. First, an IF7 peptide-displaying phage clone failed to bind 
full-length recombinant ANXA protein when the N-terminus was blocked by a 
His6-tag, whereas IF7 bound to full-length ANXA1 that was C-terminally tagged 
with His6 [14]. Second, IF7 bound to full-length ANXA1 but not to an N-terminal 
deletion delta 27 mutant [14]. Third, when IF7 peptide-displaying phage was 
injected intravenously into a tumor-bearing mouse, phage targeted the tumor 
Figure 6. 
Fluorescence micrograms of subcutaneous B16 tumor sections from mice intravenously-injected with A488-IF7. 
Tissue sections taken at 15 (upper) and 40 (lower) min after A488-IF7 injection were stained by anti-CD34 
antibody plus red fluorescence-conjugated secondary antibody to mark endothelial cells. Note that at 15 min, 
green IF7 signals are seen as punctate signals over endothelial cells, whereas at 40 min IF7 signals are in the 
stroma and seen as diffuse green fluorescence.
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vasculature, but that binding was blocked in comparable mice injected with an anti-
body raised against the ANXA1 N-terminal domain (Figure 4) [14]. Finally, in vitro 
binding assays showed that synthetic IF7 bound to a synthetic peptide representing 
the ANXA1 N-terminal domain (designated MC16), which includes 15 amino acids 
from Met1 to Glu15, plus a C-terminal Cys [25]. IF7 bound to both mouse and human 
MC16 peptides.
The molecular weight of full-length Anxa1 is 37 kDa, but Western blotting 
of endothelial plasma membranes and caveolae isolated from tumors detected 
a 34 kDa band [24]. Proteomics analysis of this 34 kDa protein suggested that it 
may lack the N-terminal domain. To determine whether the Anxa1 N-terminal 
domain is on the tumor vasculature surface, we generated a mouse monoclonal 
antibody specific to the human ANXA1 N-terminal domain (or MC16 peptide). 
Immunohistochemical analysis of various clinical specimens with anti-MC16 anti-
body revealed positive signals located at endothelial cells lining malignant tumor 
tissues in specimens from prostate, breast, lung, liver, ovarian and brain cancers 
[25], indicating that the ANXA1 N-terminus is present on endothelial cells in many 
human malignancies. Immunostaining alone did not reveal whether the antigen was 
on the cell surface or in the cytoplasm.
We confirmed that the MC16 domain was present on the luminal side of the 
plasma membrane by in vivo biotinylation of mouse brain tumors followed by 
immunoprecipitation by anti-MC16 antibody and proteomics analysis [25]. Plate 
binding assays of precipitates indicated high levels of biotinylated materials bound 
by the anti-MC16 antibody in tumor lysates, whereas biotinylated materials in 
tumor lysates treated with control antibody or those from normal liver tissue 
lysates showed significantly lower levels of biotinylated material. However, when 
immunoprecipitates from these tumors were analyzed on a protein gel followed by 
an avidin blot, we did not detect biotinylated proteins, whereas proteomics analysis 
had revealed predominantly Anxa1 peptide fragments [25]. We conclude that the 
Anxa1 N-terminal domain is cleaved from the rest of the protein and displayed on 
the tumor vasculature surface as a peptide fragment too small to be detected on a 
Western blot.
5.  Therapeutic activity of IF7 conjugated to the anti-cancer drug SN-38 
against brain tumors
Both we and others have reported that IF7-conjugated drugs show efficient 
anti-tumor activity in mouse models of tumors other than brain tumors. Examples 
include IF7-conjugated geldanamycin (GA) against prostate, lung, and breast 
cancers as well as melanoma [21], IF7-SN38 against colon cancer [21], IF7-taxol 
against breast cancer [26] and IF7-conjugated10B with boron neutron capture 
therapy against bladder carcinoma [27]. Below we focus on our studies of the effect 
of IF7-SN38 on mouse brain tumor models.
To target brain tumors, we chose to conjugate IF7 to SN-38, the active compo-
nent of irinotecan (CPT-11), which is used clinically to treat brain cancer [28, 29]. 
To compare IF7-SN38 dosages we employed a dual-tumor model, in which a single 
mouse receives luciferase gene-transfected cancer cells in brain and under the skin 
(Figure 7). Growth of tumors in both regions was quantitatively monitored using 
an IVIS imager to detect photon numbers produced by luciferase. Once tumors were 
formed in the brain and under the skin, the dual tumor model mice were injected 
intravenously with IF7-SN38 and tumor growth in both locations was assessed 
in vivo by photon number. IF7-SN38 treatment significantly suppressed tumor 
growth relative to buffer controls in both brain and under the skin at a dosage of 
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3.15 μmoles/kg. Moreover we found using either C6-Luc cells in SCID mice or B16-
Luc cells in C57BL/6 mice, intravenously-injected IF7-SN38 significantly antago-
nized growth of brain and subcutaneous tumors relative to controls at a dosage of 
7.0 μmoles/kg. When we performed similar experiments using the SN38 prodrug 
irinotecan alone at doses as high as 50 μmoles/kg, irinotecan suppressed subcutane-
ous tumor growth but only minimally suppressed brain tumor growth. Overall, 
these results indicate that in the mouse dual tumor models tested here, IF7-SN38 
suppresses brain tumor growth as effectively as subcutaneous tumor growth.
For the dual tumor model experiments (Figure 7), we had dissolved IF7-SN38 
in Cremophore EL, a non-ionic detergent used clinically to administer taxol, prior 
to injection. However, there are concerns about potential inflammatory effects of 
this detergent [30, 31]. Thus, we conducted experiments in which we dissolved 
Figure 7. 
Analysis of whether IF7-SN38 overcomes the blood–brain barrier using a dual tumor mouse model. (upper) 
schematic showing that single mice established to harbor both brain and subcutaneous tumors are injected with 
IF7-conjugated drug through the tail vein. If the drug cannot overcome the BBB, only subcutaneous tumors are 
eradicated; if drug overcomes the BBB, growth of both is suppressed. (lower) graphs show that daily injection 
of IF7-SN38 (7.0 μmoles/kg) suppressed both brain (left) and subcutaneous (right) tumor growth. Moreover, 
CPT-11, the SN-38 pro-drug, suppressed growth of subcutaneous tumors at high dosage (50 μmoles/kg) [25].
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IF7-SN38 in 10% Solutol HS15, a non-ionic surfactant with low toxicity. The 
therapeutic effect of IF7-SN38 in 10% Solutol HS15 improved significantly rela-
tive to administration with Cremophore EL (Figure 8A): B16 brain tumors began 
shrinking during the first week of daily injections at dosages as low as 2.5 μmoles/
kg, continued shrinking during the second week without drug injection, and then 
completely disappeared. Mice survived for more than 3 months after cessation of 
drug treatment without showing signs of B16-Luc cell growth in brain or other parts 
of their body, suggesting complete remission and potential involvement of host 
immune systems.
Relevant to potential immunogenicity, when we injected cells of either one of 
two isogenic lines, B16-Luc or LL/2-Luc, subcutaneously into naïve C57BL/6 mice, 
both lines produced tumors at injected site. By contrast, when either of these lines 
were injected into mice that had recovered from brain B16-Luc tumors, LL/2-Luc 
tumors grew but B16-Luc tumors did not (Figure 8B). The presence of tumor-
infiltrating lymphocytes, especially CD8+ cytotoxic T cells, is correlates with better 
Figure 8. 
IF7-SN38 treatment promotes complete remission of B16 brain tumors and a host immune response against 
tumor cells. (A) Effect of IF7-SN38 on B16-Luc brain tumors in isogeneic C57BL/6 mice. Drug dosage 
was 2.5 μmoles/kg each for IF7-SN38 and control C(RR)-SN38 diluted with 10% Solutol HS15 in water 
and administered daily for 7 days. Note that brain tumors continued shrinking after cessation of IF7-SN38 
administration in C56BL/6 mice. (B) Growth of two syngeneic cancer lines in naïve and brain-tumor-
recovered mice 4 days after subcutaneous injection of LL/2-Luc and B16-Luc cells. (C) Immunohistochemistry 
with anti-CD8 antibody of B16-Luc cells at subcutaneous injection sites, 20 hours after B16-Luc cell injection.
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prognosis of various cancers [32, 33]. Immunohistochemistry of subcutaneous 
B16-Luc injection site using an anti-CD8 antibody 20 hours after injection of naïve 
C57BL/6 mice with B16-Luc cells revealed a minimal number of CD8+ T cells at 
challenged sites. By contrast, we observed significant CD8+ cell infiltration at injec-
tion sites of B16-Luc cells in C57BL/6 mice that had recovered from B16-Luc brain 
tumors following IF7-SN38 treatment (Figure 8C). Thus it is likely that IF7-SN38 
therapy leads to complete remission in part by promoting immunological rejection 
of tumor cells by the host, preventing tumor recurrence elsewhere in the body.
6. Clinical application of IF7-SN38
As described, in mouse the Anxa1 N-terminal domain is present on the surface 
of tumor vasculature as peptide fragments. Nonetheless, such fragments should 
serve an IF7 receptor, as either the first 15 amino acid residues of ANXA1 or syn-
thetic MC16 peptide is sufficient for IF7 binding [25]. IF7 binds both human and 
mouse MC16 peptides equally, suggesting that our results with IF7 in mouse tumor 
models are relevant to humans.
Although IF7-conjugated drugs are effective in various cancer types [14, 26, 27], 
their effectiveness against brain malignancies may be particularly high as gene 
expression data indicates ANXA1 overexpression in brain tumors [34, 35], a finding 
supported by immunohistochemistry with anti-MC16 antibody [25]. Moreover, as 
IF7 targets tumor vasculature and overcomes the BBB, IF7-conjugated drug would 
accumulate in brain tumor cells, a critical advantage over low molecular weight 
drugs like temozolomide, which does not target brain tumors and must be adminis-
tered at high doses (Figure 9).
We found the effective dosage of IF7-SN38 in the mouse brain tumor models to 
be 2.5 μmoles (5.35 mg)/kg (Figure 8), which translates into a human equivalent 
[36] of 0.43 mg/kg or SN-38 0.079 mg. This dosage is considerably lower than that 
currently recommended for CPT-11 (the SN-38 pro-drug) administered to cancer 
patients, namely, 120 ~ 200 mg/m2 or 2.91 ~ 4.85 mg/kg [37, 38]. Anticipated 
doses of IF7-SN38 in humans are also unlikely to be toxic at pharmacologically 
active dosage.
Figure 9. 
Mode of action of chemotherapeutics directed against brain tumors. General chemotherapeutics do not 
penetrate brain tumors due to the BBB and thus are administered to patients at high dosage. Some low 
molecular weight chemotherapeutics such as temozolomide penetrates the brain but requires high dosage, 
because temozolomide does not target brain tumors. IF7-SN38 targets brain tumors and overcomes the BBB. 
At low dosage, IF7-SN38 becomes concentrated in tumors, including brain tumors, and exhibits therapeutic 
activity.
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7. Conclusions and future perspectives
Historically, reagents like IF7 emerged with the advent of carbohydrate mimetic 
peptides [15, 16]. The surprising finding that Anxa1 is an I-peptide receptor led 
us to identify IF7 [14, 21]. When IF7 was injected intravenously into brain tumor-
bearing mice, it targeted tumor vasculature by binding the Anxa1 N-terminal 
domain and then crossed the vasculature via transcytosis, to overcome the BBB. 
Due to its highly specific tumor vasculature targeting activity, IF7-SN38 eradicated 
brain tumors at low dosage, initiating an immune reaction against cancer cells, fol-
lowed by complete remission of brain tumors [25]. A similar host immune reaction 
was also found in IF7-conjugated boron neutron capture therapy in a mouse bladder 
carcinoma model [27].
IF7-SN38 is, however, susceptible to esterases and proteases. To circumvent sta-
bility issues, we have developed an ANXA1-binding D-peptide, designated dTIT7 
[39]. We have found that GA-dTIT7, in which geldanamycin is conjugated to dTIT7 
through an esterase-resistant linker, is orally administrable and suppresses brain 
tumor growth in the mouse.
Cancer treatments are increasingly expensive due to development of sophisticated 
diagnostics and therapies. IF7-SN38 can be chemically synthesized cost-effectively 
and is stable as a dry powder. Furthermore, orally-administrable peptide-conjugated 
drugs would be advantageous in societies that lack infrastructure required for costly 
treatment. Further development of peptide-conjugated drugs could reveal additional 
candidates with clinical applications against intractable cancers.
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